Siplizumab Explained

Siplizumab (MEDI-507) is an investigational monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and has been tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.[1] [2] [3] [4] [5]

References

  1. Podestà . Manuel A. . Binder . Christian . Sellberg . Felix . DeWolf . Susan . Shonts . Brittany . Ho . Siu-Hong . Obradovic . Aleksandar . Waffarn . Elizabeth . Danzl . Nichole . Berglund . David . Sykes . Megan . Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro . American Journal of Transplantation . January 2020 . 20 . 1 . 88–100 . 10.1111/ajt.15533. free . 31319439 . 6940533 .
  2. Langley . Richard G. . Papp . Kim . Bissonnette . Robert . Toth . Darryl . Matheson . Robert . Hultquist . Micki . White . Barbara . Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies . International Journal of Dermatology . July 2010 . 49 . 7 . 818–828 . 10.1111/j.1365-4632.2010.04512.x. 20618506 . 21145758 .
  3. O'Mahony . Deirdre . Morris . John C. . Stetler-Stevenson . Maryalice . Matthews . Helen . Brown . Margaret R. . Fleisher . Thomas . Pittaluga . Stefania . Raffeld . Mark . Albert . Paul S. . Reitsma . Dirk . Kaucic . Karen . Hammershaimb . Luz . Waldmann . Thomas A. . Janik . John E. . EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies . Clinical Cancer Research . 1 April 2009 . 15 . 7 . 2514–2522 . 10.1158/1078-0432.CCR-08-1254. free . 19293260 . 7322623 .
  4. Adkins . Douglas . Ratanatharathorn . Voravit . Yang . Harry . White . Barbara . Safety Profile and Clinical Outcomes in a Phase I, Placebo-Controlled Study of Siplizumab in Acute Graft-Versus-Host Disease . Transplantation . 27 July 2009 . 88 . 2 . 198–202 . 10.1097/TP.0b013e3181abfbf7. free . 19623014 .
  5. Cvetkovski . Filip . Razavi . Ronia . Sellberg . Felix . Berglund . Erik . Berglund . David . Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro . American Journal of Transplantation . October 2023 . 23 . 10 . 1603–1611 . 10.1016/j.ajt.2023.05.032. free . 37270108 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Siplizumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.